Not Disclosed

Drug Name: Not Disclosed
Company: Aquinnah Pharmaceuticals
Location: US-Massachusetts
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease
Mechanism Type: Stress granule clearance
Mechanism: Aquinnah is developing compounds that eliminate TDP-43-positive stress granules which are estimated to persist in more than 75% of cases of the disease.
U.S. Status for ALS: Preclinical

[1] Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda Pharmaceuticals To Advance New Therapies in ALS. PR Newswire, 21 Dec 2015. Accessed 28 Dec 2015 from

Last updated December 28th, 2015

Share this: